A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: A randomized controlled study

American Journal of Gastroenterology

Volumn 102, Issue 7, 2007, Pages 1397-1405

  Spahr, Laurent ^a,b   Giostra, Emiliano ^a   Frossard, Jean Louis ^a   Morard, Isabelle ^a   Mentha, Gilles ^a   Hadengue, Antoine ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b ElectroEncephaloGraphie et Eval Prechirurgicale de l'ePilepsie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALCOHOL; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; ENDOTHELIN 1; OCTREOTIDE; PLACEBO; VASCULOTROPIN;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BACTERIAL PERITONITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; FATTY LIVER; FEMALE; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; INJECTION SITE REACTION; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; ENDOTHELIN-1; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; HYPERTENSION, PORTAL; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRAMUSCULAR; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OCTREOTIDE; PORTAL PRESSURE; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UROTENSINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34250879185     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01262.x     Document Type: Article

References (46)

1. Lebrec D, Vinel JP, Dupas JL. Complications of portal hypertension in adults: A French consensus. Eur J Gastroenterol Hepatol 2005 17 : 403 10.
2. Lamberts SW, Van Der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med 1996 334 : 246 54.
3. Baik SK, Jeong PH, Ji SW, et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: A randomized comparison. Am J Gastroenterol 2005 100 : 631 5.
4. McCormick PA, Biagini MR, Dick R, et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: A double-blind, placebo-controlled study. Hepatology 1992 16 : 1180 6.
5. Corley DA, Cello JP, Adkisson W, et al. Octreotide for acute esophageal variceal bleeding: A meta-analysis. Gastroenterology 2001 120 : 946 54.
6. Hadengue A. Somatostatin or octreotide in acute variceal bleeding. Digestion 1999 60 (Suppl 2) : 31 41.
7. Nishida H, Giostra E, Spahr L, et al. Validation of color Doppler EUS for azygos blood flow measurement in patients with cirrhosis: Application to the acute hemodynamic effects of somatostatin, octreotide, or placebo. Gastrointest Endosc 2001 54 : 24 30.
8. D'Amico G, Politi F, Morabito A, et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double-blind, randomized pragmatic trial. Hepatology 1998 28 : 1206 14.
9. Albillos A, Rossi I, Iborra J, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994 21 : 88 94.
10. Vorobioff JD, Gamen M, Kravetz D, et al. Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: A randomized, controlled trial. Gastroenterology 2002 122 : 916 22.
11. Lawnicka H, Stepien H, Wyczolkowska J, et al. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000 268 : 567 71.
12. Fort J, Oberti F, Pilette C, et al. Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats. Hepatology 1998 28 : 1525 31.
13. Chan CC, Lee FY, Wang SS, et al. Chronic administration of octreotide ameliorates portal hypertension and portal hypertensive gastropathy in rats with cirrhosis. Clin Sci (Lond) 1998 94 : 367 71.
14. Kotzampassi K, Koufogiannis D, Eleftheriadis E. Sustained reduction of portal pressure by administration of octreotide-LAR in portal hypertensive rats. Hepatol Res 2001 19 : 108 16.
15. Wang SS, Lee FY, Wu SL, et al. Effects of long-term administration of octreotide on sodium retention and atrial natriuretic peptide in carbon tetrachloride-induced cirrhotic rats. J Hepatol 1997 26 : 1128 34.
16. Ottesen LH, Aagaard NK, Kiszka-Kanowitz M, et al. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: A randomized, double-blind, controlled trial. Hepatology 2001 34 : 471 7.
17. Jenkins SA, Baxter JN, Critchley M, et al. Randomised trial of octreotide for long-term management of cirrhosis after variceal haemorrhage. BMJ 1997 315 : 1338 41.
18. D'Amico G, Garcia-Pagan JC, Luca A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: A systematic review. Gastroenterology 2006 131 : 1611 24.
19. Angermayr B, Mejias M, Gracia-Sancho J, et al. Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. J Hepatol 2006 44 : 1033 9.
20. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: Anything worth doing should be done right. Hepatology 2004 39 : 280 2.
21. Spahr L, Giostra I, Morard I, et al. Perendoscopic variceal pressure measurement: A reliable estimation of portal pressurein patients with cirrhosis? Gastroenterol Clin Biol 2006 30 : 1012 8.
22. Huet PM, Pomier-Layrargues G. The hepatic venous pressure gradient: "Remixed and revisited." Hepatology 2004 39 : 295 8.
23. Gonzalez-Abraldes J, Garcia-Pagan JC, Bosch J. Nitric oxide and portal hypertension. Metab Brain Dis 2002 17 : 311 24.
24. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005 43 : 167 76.
25. Patch D, Burroughs A. Octreotide for cirrhosis after variceal bleeding. Authors' claims for octreotide were not justified. BMJ 1998 316 : 1607.
26. Valla D, Flejou JF, Lebrec D, et al. Portal hypertension and ascites in acute hepatitis: Clinical, hemodynamic and histological correlations. Hepatology 1989 10 : 482 7.
27. Pomier-Layrargues G, Villeneuve JP, Willems B, et al. Systemic and hepatic hemodynamics after variceal hemorrhage: Effects of propranolol and placebo. Gastroenterology 1987 93 : 1218 24.
28. Vorobioff J, Groszmann RJ, Picabea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: A 10-year prospective study. Gastroenterology 1996 111 : 701 9.
29. Luca A, Garcia-Pagan JC, Bosch J, et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997 112 : 1284 9.
30. Poynard T, Degott C, Munoz C, et al. Relationship between degree of portal hypertension and liver histologic lesions in patients with alcoholic cirrhosis. Effect of acute alcoholic hepatitis on portal hypertension. Dig Dis Sci 1987 32 : 337 43.
31. Bell H, Jahnsen J, Kittang E, et al. Long-term prognosis of patients with alcoholic liver cirrhosis: A 15-year follow-up study of 100 Norwegian patients admitted to one unit. Scand J Gastroenterol 2004 39 : 858 63.
32. Lin HC, Tsai YT, Lee FY, et al. Comparison between portal vein pressure and wedged hepatic vein pressure in hepatitis B-related cirrhosis. J Hepatol 1989 9 : 326 30.
33. Perello A, Escorsell A, Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 1999 30 : 1393 7.
34. Bureau C, Peron JM, Alric L, et al. "A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002 36 : 1361 6.
35. Lebrec D. Pharmacological treatment of portal hypertension: Hemodynamic effects and prevention of bleeding. Pharmacol Ther 1994 61 : 65 107.
36. Gonzalez-Abraldes J, Albillos A, Banares R, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001 121 : 382 8.
37. Banares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002 36 : 1367 73.
38. Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001 120 : 161 9.
39. Sanyal AJ. Octreotide and its effects on portal circulation. Gastroenterology 2001 120 : 303 5.
40. Malesci A, Tacconi M, Valentini A, et al. Octreotide long-term treatment in patients with portal hypertension: Persistent inhibition of postprandial glucagon response without major changes in renal function. J Hepatol 1997 26 : 816 25.
41. Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology 2001 120 : 975 83.
42. Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992 327 : 1774 8.
43. Tripathi D, Therapondos G, Ferguson JW, et al. Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: A randomised controlled trial. Gut 2006 55 : 1290 5.
44. Salcedo X, Medina J, Sanz-Cameno P, et al. Review article: Angiogenesis soluble factors as liver disease markers. Aliment Pharmacol Ther 2005 22 : 23 30.
45. Fernandez M, Mejias M, Angermayr B, et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005 43 : 98 103.
46. Abraldes JG, Iwakiri Y, Loureiro-Silva M, et al. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 2006 290 : G980 7.